Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

gram (304) and two Ambulatory Blood Pressure Monitoring (ABPM) studies (111 and 112), which showed naproxcinod's favorable 24-hour blood pressure profile. - Signature of two commercial supply agreements for naproxcinod with world leading manufacturing companies: DSM for the production of active pharmaceutical ingredient (API) and Capsugel for the production of naproxcinod capsules. - Further progress in the collaboration with Merck & Co., Inc., following the initiation of a series of phase 1b studies in mild to moderate hypertensive volunteers, which have the aim of selecting the most appropriate compound to advance into phase 2. - Two phase 2 studies for PF-03187207 in glaucoma patients conducted by Pfizer Inc demonstrated an improvement over Xalatan(R) 0.005%, in terms of intraocular pressure lowering, but did not reach statistical significance on the primary endpoint.

Eric Castaldi, Chief Financial Officer of NicOx, commented: "As planned, we successfully completed the phase 3 clinical program for naproxcinod in 2008. We believe that the attractive profile of naproxcinod achieved in the phase 3 program should ensure our compound's future commercial success. Our balance sheet has enabled us to continue to expand the pre-commercialization activities for naproxcinod in parallel with the ongoing partnering discussions. We project cash burn will substantially decline throughout 2009, following the completion of the phase 3 program, and we currently believe we have sufficient cash to finance the activities of the Company until the end of 2010. This projection does not include the possible upfront and milestone payments we expect from a potential commercialization agreement for naproxcinod."

Financial summary of 2008

Revenues for the full year 2008 were EUR3.4 million, compared to EUR20.6 million in 2007. These
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... /CNW/ - A new national Labour Market Information (LMI) ... profiles of new graduates entering the biotech sector. The ... for New Grads in Biotech," is sponsored in part ... (Rx&D) and features data collected from new graduates that ... from 2013 to 2015. Among the interesting ...
(Date:3/30/2015)... , March 30, 2015 ... novel biological drugs to treat cancer, viral infections ... Professor Sir John Bell , the Regius ... of the Office for the Strategic Coordination of ... immediate effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
(Date:3/29/2015)... 2015  Caris Life Sciences® today announced the ... Intelligence®, the company,s panomic, comprehensive tumor profiling service, ... rare and difficult to treat gynecological cancers may ... to improve patient outcomes. These studies were presented ... of Gynecologic Oncology (SGO) 2015 Annual Meeting on ...
(Date:3/27/2015)... Cranston, RI (PRWEB) March 27, 2015 ... for the promotion of hair regrowth in adult ... Savin classifications I-II or Norwood Hamilton classifications of IIa-V ... In an industry plagued by products that over-promise and ... the Capillus272Pro™, renewing faith and confidence among more than ...
Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2
... BPUR ) announced today the pricing of an underwritten ... the,underwriters have agreed to purchase from the company 16,850,000 ... an additional 16,850,000,new shares. The price for one share ... each warrant is $1.06. This transaction is expected to,close ...
... and armed forces into Robocops, repelling the force of bullets ... could give those in the line of fire materials which ... , A research paper published in the Institute of Physics ... Technology at the University of Sydney have found a way ...
... (Nasdaq:,SNMX), a leading company focused on using proprietary ... the packaged food and,beverage industry, announced today that ... Inc. will conclude on December 9,2007, which is ... the existing,agreement. The conclusion of this collaboration does ...
Cached Biology Technology:Biopure Announces Pricing of Equity Offering 2Using nanotech to make Robocops 2Senomyx Announces Conclusion of Discovery and Development Collaboration With Kraft Foods Global, Inc. 2Senomyx Announces Conclusion of Discovery and Development Collaboration With Kraft Foods Global, Inc. 3
(Date:3/16/2015)... Germany , March 16, 2015 ... Identification Systems GmbH will present groundbreaking innovations in ... Hanover, Germany .      ... DERMALOG,s latest biometric innovation is well at the ... next generation e-gate made in Germany ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... eyes sensitive to ultraviolet light, which they may use to ... new Nova Southeastern University study suggests. Tamara Frank, Ph.D., ... Oceanographic Center, who is the principal investigator of the study, ... dark area at the ocean bottom ---- may be using ...
... should become increasingly lighter, with the same stability, and ... superbly suited for the needed lightweight design, because it ... also betray a disadvantage: with increasing strength their susceptibility ... might form as the welded joints cool off ...
... This press release is available in Spanish . ... Atlantic Tuna (ICCAT) is to invest 1.5 million euros in ... co-ordinated in 2012 by AZTI-Tecnalia, the technological centre specialised in ... In the first project, the consortium co-ordinated by AZTI-Tecnalia ...
Cached Biology News:Deep-sea crabs seek food using ultraviolet vision 2Deep-sea crabs seek food using ultraviolet vision 3Manufacturing crack-resistant lightweight components 2AZTI-Tecnalia leads 2 research projects on bluefin tuna with 1.5 million euros investment 2